Will Chinese-Made COVID-19 Vaccines Find Acceptance in Nigeria?

 In analysis, op-ed

It is widely accepted that vaccination is one of the most important achievements in public health. Yet, in the face of this ‘consensus’, vaccines are constantly challenged by individuals and groups on religious, and even political grounds.

The determinants around vaccine acceptance or hesitance usually include public trust, the source of the vaccine, and socioeconomic factors such as cost. In Nigeria, these factors hold true for COVID-19 vaccines, including Chinese-made vaccines.

What Is the Current COVID-19 Situation in Nigeria?

Nigeria recorded its first COVID-19 case on February 27, 2020. Since then, Nigeria has fared relatively well in its COVID-19 response. Comparatively, South Africa has been severely affected with 1.51 million cases and 49,993 deaths. This success is largely due to Nigeria adopting an early response, by implementing social distancing measures before 50 cases were recorded and enforcing a full lockdown on March 30, 2020.

The Nigerian federal government also created a COVID-19 intervention fund, which equated to N500 billion (US$1.4 billion, equating to 0.3% of GDP), to divert financial resources to combat challenges by COVID-19. Other government initiatives include an N2.3 trillion (US$5.9 billion, 1.5% of GDP) COVID-19 stimulus package to mitigate longer-term economic impacts induced by the pandemic, with a focus on sustainable economic recovery.

In terms of vaccines, the Nigerian government aims to vaccine 40% of its total population in 2021, with an additional 30% in 2022, to achieve an overall goal of 70% of the population to be vaccinated. Assuming that the vaccine can be purchased for $3 per dose, the maximum ceiling cost set by COVAX for low and middle-income countries would cost $844.2 million to vaccinate 70% of Nigeria’s population of 201 million with two doses. However, when factoring in that 54.2% of Nigeria’s population is under 20 years old, meaning a significant number are unable to accept the vaccine (recipients must be aged 18+), the cost of a 70% vaccination rate falls to $386.6 million for the population aged 20+. Alternatively, if each dose cost US$19, the same as Senegal recently paid for doses of SinoPharm, it would cost Nigeria $2.4 billion to vaccinate 70% of the population aged 20+.

The Nigerian Government’s Attitude Towards a Chinese Vaccine

The Nigerian government’s attitude towards vaccines has been very pragmatic, more so as Nigeria was not shortlisted for the WHO’s COVAX Pfizer-BioNTech vaccine sharing formula, nor is Nigeria currently planning to produce vaccines locally.

During the visit of Wang Yi, the Chinese Foreign Minister, to Nigeria back in January, the Nigerian Minister of Foreign Affairs Geoffrey Onyeama  said that Nigeria is in talks with China to acquire Chinese-made vaccines. But so far, Nigeria has only received 4 million doses of the AstraZeneca vaccine through COVAX, despite other African countries, including Nigeria’s West Africa neighbour Senegal, already receiving Chinese vaccines. Furthermore, with the cost of Senegal’s SinoPharm vaccine order high at nearly US$19 per dose, it equated to a total of US$3.72 million for 200,000 doses. Equatorial Guinea, another neighbouring country, also received a donation of 100,000 doses of the SinoPharm vaccine.

So, what is the issue?

Well, a major concern shared by both government officials and the Nigerian public is the regulatory processfor vaccines before they are used locally.  Ben Igbakpa, a member of the Nigerian House of Representatives shared his opinion;

“The matter is not the origin of the vaccine but the efficacy of the vaccine subject to certification by NAFDAC, SON, NMA and all relevant regulatory authorities in Nigeria. If the vaccines from China pass all regulatory tests and are approved by the WHO, there should not be an opposition to it.”

Igbakpa added that “The national interest is to safeguard the lives of Nigerians and shore up the immunity of Nigerians against the deadly virus.”

The Nigerian Minister of Health, Dr. Osagie Ehanire, announced on February 24 that Nigeria is expecting COVID-19 vaccines from three donor sources; COVAX, the Global Alliance for Vaccines and Immunization (GAVI), and African Vaccine Acquisition Task Team (AVATT) set up by the African Union. These sources should satisfy the needs of the country without having to procure more. Dr Ehanire continued by stating;

“Now, you can see that all of these are coming from various sources but put together, they almost satisfy our needs so that we don’t really need to go procure. But the question is, when are they delivering? That is not in our hands. It is in the hand of the person who is bringing it to us.”

The Nigerian Public Attitude Towards Chinese Vaccines

Unlike in some areas of the world, the Nigerian government is not under immense public pressure to commence a national vaccination programme. This is in part because, as mentioned, Nigeria has fared well in its COVID-19 response, with a relatively low prevalence of cases and deaths. However, recent discussions and debates concerning vaccines have also played a central role, as public concerns and uncertainty around vaccines have led to an increasing number of people questioning the veracity of vaccine safety, seeking alternatives to vaccines, or even refusing vaccination.

A recent study by Malik Sallam M.D. from the Jordan University Hospital provides an overview of global COVID vaccine hesitancy. The analysis, which includes data from 30 studies, reveals Nigeria has an acceptance rate of 65.2%, which is significantly lower compared to South Africa’s acceptance rate of 81.6%. Another recent piece in the American Journal of Medical Sciences and Medicine revealed that only 51% of Nigerians (499 total surveyed, aged between 19-35) were willing to take a COVID-19 vaccine while 30% were not willing, with 18% being indecisive. Other studies have shown that unreliable clinical trials, self-trust in the personal immune system, and skepticism towards a potential COVID-19 vaccine, were listed as the top reasons for non-acceptance in Nigeria.

Local media have generally avoided politicizing the COVID-19 vaccines and have played an important role in sensitizing the public about COVID-19 and the importance of vaccines. Yet, earlier this month, The Guardian, a widely read newspaper in Nigeria, published an article that questions the safety of the SinoPharm vaccine, which will likely cause distrust of Chinese-made vaccines.

What Other Issues Are Impacting the Vaccine Rollout in Nigeria?

Coupled with skepticism, cost plays a general role in what vaccine is deemed suitable for Nigeria’s COVID-19 vaccination program. There is an assumption that Chinese vaccines are cheaper than vaccines from other vendors. This alongside the fact that SinoPharm’s vaccine does not require storage in ultra-cold freezers, has resulted in SinoPharm’s vaccine seeming a natural choice, alongside the AstraZeneca and Sputnik V vaccines. However, the WHO approving AstraZeneca’s COVID-19 vaccine for use will have an impact on the preference of Nigerians.

“There’s skepticism towards COVID-19 vaccines in general, but people will be far more open to a WHO-approved vaccine than a similar vaccine without WHO approval,” says Iguehi Omole-Irabor, a program officer at The Kukah Center, an independent policy center in Abuja which is currently working on a COVID-19 project involving several states in Nigeria.

So, What Role Can Chinese Partners Play in Addressing the Concerns of the Nigerian Government and the General Public?

Firstly, addressing limited public trust can be overcome through Chinese partners, including the Ministry of Health and other related government agencies, sharing timely clinical information on Chinese-made vaccines. In the early stages of the pandemic, China’s Public Health and Customs Departments shared vital information with health leaders from 20 African countries. Extending this knowledge-sharing support regarding vaccines will help establish trust amongst the general public. Building on this, as China has already commenced its vaccine rollout, relevant government agencies and healthcare actors should share knowledge on how to distribute vaccines safely and efficiently to minimize costs and maximize vaccine uptake.

Secondly, whilst Chinese-made vaccines are approved by the Chinese regulator, the National Medical Products Administration, vaccine producers should also seek to put their respective vaccines through the WHO regulatory process to achieve WHO approval. A WHO-approved vaccine, like AstraZeneca, is more likely to increase the public’s trust due to WHO-backing, and therefore reduce overall levels of vaccine skepticism. As a report by the ACDC with the London School of Hygiene & Tropical Medicine highlighted, 79% of respondents across 15 African countries, including Nigeria, would be willing to take a COVID-19 vaccine considering it was deemed safe and effective. However, the survey demonstrated a fluctuation in the valuation and trust amongst different international organizations. For instance, the WHO is ranked as the top trusted voice for providing safe messages, whereas the ACDC had a lower trust recognition. As such, Chinese vaccine producers, and the ACDC, should seek to partner with trusted sources like the WHO to convey safety messages regarding vaccines to the general public.

Thirdly, local manufacturing can play an important role in building confidence too. Faster delivery now is key and only three countries in Africa are planning to manufacture international vaccines – Morocco (the Chinese vaccine), Egypt (Russian vaccine), and South Africa (US Johnson & Johnson vaccine). Local manufacturing can scale up output,  create jobs and reduce costs in the long run. Investing in local manufacturing beyond Morocco will also build trust.

Overall, the primary issue regarding COVID-19 vaccination in Nigeria concerns a lack of confidence in a novel vaccine. This is combined with safety doubts due to the unfortunate history of vaccine accidents in Nigeria, Kenya, and other developing countries, which had little to no reparations to dispense justice or hold necessary individuals/organizations responsible. Uninformed media reports, in combination with lack of access to multiple knowledge perspectives, also play a role in vaccine refusal. This attitude is extended towards COVID-19 vaccines in general, including the Chinese vaccines. Yet, there are ways to overcomes these hurdles, and Chinese support regarding information-sharing will be central for both increasing public trust in Chinese-manufactured vaccines and an efficient vaccine rollout.

Ovigwe Eguegu is an Abuja-based international security analyst and DR policy analyst.

This article was originally published on the China Africa Project website on 12 March 2021

Recommended Posts

Leave a Comment

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

EDMOND BOSILONG

Research Analyst

Edmond is a research analyst who is passionate about sustainable development, innovation, and the environment. Passionate about climate financing, he firmly believe there is a more reliable system to promote equality, growth, and welfare in societies without affecting the ecosystem. Through his skills, knowledge and experienced gained over 7 years, he wants to make an impact in the world of development. Edmond holds a Master’s Degree in Public Policy from Korea Development Institute and a BA Degree (Honors) in Business from University of Derby.

   HANNAH RYDER

    Founder and CEO

Hannah Ryder is the Founder & CEO of Development Reimagined. A former diplomat and economist with 20 years of experience, named one of 100 most influential Africans in 2021, she is also Senior Associate for the Africa Program of the Center for Strategic International Studies (CSIS), sits on the Board of the Environmental Defence Fund, and is a member of UAE's International Advisory Council on the New Economy. Prior to her role at DR, Ms Ryder led the United Nations Development Programme (UNDP)’s work with China to help it scale up and improve its cooperation with other developing countries, including in Africa. She has also played various advisory roles for the UN and OECD and co-authored the seminal Stern Review of the Economics of Climate Change in 2006.

LEAH LYNCH

Deputy Director

Leah Lynch is Deputy Director of Development Reimagined (DR), and head of the China office. Leah has over 10 years of experience in development and has lived in China for over 8 years. Leah has also travelled extensively around Asia and Africa for research. Leah supports the strategic direction of the team across China, with a mission to deliver high quality research on sustainable development and poverty reduction. Leah is also Chair of the Sustainability Forum at the British Chamber of Commerce in China, providing direction on sustainability initiatives for British and Chinese business. Leah has also consulted on various evaluations on UK aid (ICAI) and is a specialist on development cooperation from the UK and China. Leah has also consulted on various UN projects, including providing support to the UN China team during the COVID-19 Pandemic. Prior to DR, Leah was at the United Nations Development Programme (UNDP) China, supporting the UN’s portfolio on communication strategies, China’s South- South Cooperation and the Belt and Road Initiative (BRI). Before UNDP, Leah lived and worked in Kenya developing sustainable water policies for the Kenyan government.

YIKE FU

China-Africa Policy Analyst

Yike Fu is a Policy Analyst and has been responsible for leading numerous areas of work, including on debt analysis in Africa and beyond, and China-Africa trade and investment logistics and analysis. She is the co-author of “African Debt Guide”, in which she challenged the narrative that Africa is in the midst of a new debt crisis by analysing data back to the 1970s and adopting new metrics to present the real story behind the data. She also developed a benchmark to compare the financial distribution of development partners such as the UK, US, Japan, France and China in Africa. Prior to her role at DR she worked at the International Finance Corporation and African Union Representational Mission to the US. She holds a Masters in International Affairs from George Washington University.

JUDITH MWAI

Research Analyst

Judith is a Research and Policy Analyst, where she specialises in Africa-China relations, international development, and diplomacy. During her time at Development Reimagined, Judith has co-authored several articles published in The Diplomat on debt and China-Barbados relations and was quoted by China Daily in a piece on Women Rights in China. Previously, Judith worked as a research analyst for an Advocate and Commissioner and Oats office in Kenya.

OVIGWE EGUEGU

Policy Analyst

Ovigwe specialises in geopolitics with particular reference to Africa in a changing Global Order. He is adept at critically analysing the politics of contemporary development processes and providing insight into the geopolitical interests that influence them. His work includes research, publications, tailored briefings and advising on global and regional trends, and issues at the nexus of geopolitics and development. Ovigwe appears frequently in media around the world such as Al Jazeera, TRT World, SABC, CGTN, BBC Radio, and other platforms.

JING CAI

Policy Analyst

Jing leads China-African health and agriculture cooperation research at Development Reimagined, having managed our FOCAC Policy Analysis and Advocacy project. She is also the co-author of “China-Africa Health Cooperation under FOCAC Umbrella”, in which she analysed China’s commitments around health cooperation since the first FOCAC summit and deepdived into four African countries’ health overview, challenges and cooperation with China as cases studies. Before DR, Jing worked at GIZ Cambodia on M&E of a disability advocacy project. She also worked as a translator with Chinese medical team in Benin.

PATRICK ANAM

Trade Policy Analyst

Patrick is an International Trade Policy and Trade Law Expert with over 5 years of experience. His expertise includes trade law, trade policy analysis and regional integration. He is currently engaged with Development Reimagined as a Senior Trade Analyst and was the lead author of Development Reimagined's recent Report on Africa-China Relations titled "From China-Africa to Africa- China: A Blue Print for a Green and Inclusive Continent-Wide Strategy Towards China." and “Reimaging FOCAC Going Forward.” Patrick has previously consulted for the East African Community, UNECA and for the Kenya Ministry of Trade.

ROSIE FLOWERS

Senior Policy Analyst 

Rosemary is our Senior Policy Analyst. She is a skilled policy analyst and has previously worked as a UK civil servant. She is studying Human Rights at Birkbeck, University of London with a research focus on international law in the context of health crises such as the COVID-19 pandemic.

JADE SCARFE

Project Manager and Africa-China Communication Assistant

Jade is a Project Manager for Development Reimagined’s flagship project Africa Unconstrained, which focuses on financing needs and debt vulnerabilities of African countries. Her research focuses on China-Africa development finance alongside debt vulnerabilities, infrastructure needs and South-South cooperation. She has worked with a breadth of stakeholders from China, Africa and the wider international community, including governments, private sector, NGOs and civil society. Her writing has appeared in a number of publications, including The Africa Report, The China-Africa Project, The Diplomat and more. Jade holds a Master’s in China and Globalisation studies from King’s College London.

ROSIE WIGMORE

Programme Manager

Rosie is the Project Manager of Africa Reimagined (AR) at Development Reimagined (DR) where she supports high-end African brands with entering the Chinese market by operating services such as trademark protection, Chinese market research, Chinese partnership building, and Africa to China logistical support and import/export services. Rosie has worked with DR for over two years now with proven success in helping high-end African brands navigate the Chinese market. She is extremely passionate about her work because more African brands selling in the Chinese marketplace means African countries can export MORE value-added goods, create MORE jobs and foster MORE innovation in African countries.

Rosie is also alumni of the School of International Studies at Peking University in Beijing where she is also an editor at the Peking Africa Think Tank. PATT is led by a diverse group of scholars who specialise in African Studies within the context of Sino-Africa relations.

LAUREN ASHMORE

Consultant

Lauren has lived in six countries from the Americas to Europe and Asia and speaks both French and Spanish proficiently. At Development Reimagined, Lauren’s research focuses on climate action both in the Asia-Pacific and in Africa, and how countries are using tools such as SDGs and Covid-19 action to build a more climate-resilient future. She holds a Masters in International Relations from Leiden University.

ETSEHIWOT KEBRET

Consultant

Etsehiwot holds a Masters’s degree in Development Studies from the London School of Economics. She has diverse experience in humanitarian and development issues by working in both multilateral organizations and international non-governmental organizations. Etsehiwot is currently a consultant focusing on the SDGs and development finance.

DIBEKULU MULU

Economist Consultant

Dibekulu is an economist by training. He holds an MSc in International Development Studies from Palacky University Olomouc, an MSc in Development Economics from the University of Clermont Auvergne, and an MSc in Economics, Finance, and International Integration from the University of Pavia. At Development Reimagined, he works as an Economist consultant. He has strong data analysis skills, with research interests centring around development finance, impact assessment, food security, and agricultural insurance.

OSARU OMOSIGHO

Project Manager

Osaru is a health professional with an MSc in Health Systems Policy and an interest in women’s health and population management. At Development Reimagined, she applies her health sector experience to global health research and collating locally applicable development insights from China.

PIER FERDINANDO CINOTTO

Research Analyst

Ferdinando’s research at Development Reimagined is centred on South-South Cooperation dynamics, specifically on the analysis of Chinese investment and debt flows in Africa and their linkages to African industrialisation. He is currently a Yenching Scholar at Peking University, after having graduated from the University of Cambridge with an MPhil in Development Studies.

DAVID TINASHE NYAGWETA

Research Analyst

David is a Research and data analyst at Development Reimagined. His scholarly focus is mostly on interdisciplinary research in demographic economics and development with interests in migration, economic development and policy, education, health and subjective well-being. He is currently a PhD scholar at Nelson Mandela University from which he also holds B.com Economics and Statistics and M.com respectively.

IVORY KAIRO

Research Analyst Kenya

Ivory is a Kenyan lawyer with experience in policy research and analysis. She also supports the communications team at DR. Ivory speaks English, Swahili and French.

JOY ENE

Research And Data Analyst China 

Joy Ene is a Research and Data Analyst at DR. Joy is passionate about African/global development, poverty eradication and trade policies between underdeveloped and developing countries. She is also a fourth-year student of International Economics and Trade at the  Liaoning University, Shenyang, China. She serves as the President of the Student Union, Liaoning University, International Students chapter.

CHENSI LI

Research Analyst 

Chensi Li is a research analyst. She has previously worked for local NGOs in Nigeria and Cameroon and think-tanks in China.  Her research areas include Sino-African relations, African foreign affairs, public diplomacy, state-building and national governance.

Yixin Yu

Research Analyst 

Yixin is a Junior Research Analyst and her focus areas is on public-private partnership and entrepreneurship. She has over three years of working experience in both private and public sectors in Ethiopia. She was the China Liaison Officer for project ‘Partnership for Investment and Growth in Africa’ at International Trade Centre, where she accumulated rich experience in investment and trade promotion

HANNAH RYDER

Founder and CEO

Hannah Ryder is the Founder & CEO of Development Reimagined. A former diplomat and economist with 20 years of experience, named one of 100 most influential Africans in 2021, she is also Senior Associate for the Africa Program of the Center for Strategic International Studies (CSIS), sits on the Board of the Environmental Defence Fund, and is a member of UAE's International Advisory Council on the New Economy. Prior to her role at DR, Ms Ryder led the United Nations Development Programme (UNDP)’s work with China to help it scale up and improve its cooperation with other developing countries, including in Africa. She has also played various advisory roles for the UN and OECD and co-authored the seminal Stern Review of the Economics of Climate Change in 2006.